CCR

TBK1degrader-4 (Compound 30) is a molecular glue degrader targeting TBK1. It effectively inhibits cyst growth, reduces inflammation, and lowers levels of pro-inflammatory factors such as Ccl2, IFNβ, and IL-6. TBK1degrader-4 shows potential for research in autosomal dominant polycystic kidney disease (ADPKD).

Zn-DPA-maytansinoid 1 targets checkpoints, shrinks tumors, and heats TME.

CHS-114 (SRF-114) is a fully human IgG1 antibody targeting the (CCR8) receptor. It shows potential for research in head and neck squamous cell carcinoma (HNSCC). The isotype control for CHS-114 can be referred to as HumanIgG1kappa, Isotype Control.

Met-RANTES (human) acetate is the acetate salt form of Met-RANTES (human). It acts as an antagonist for CCR1 and CCR5 receptors. This compound inhibits the human chemokines MIP-1α and MIP-1β, with respective IC50 values of 5 and 2 nM. Additionally, Met-RANTES (human) acetate reduces bone destruction and alleviates adjuvant-induced arthritis (AIA) in rats.

CKLF1-C27 peptide activates ERK1/2 via CCR4, competes with CKLF1, promotes HUVEC growth, and has psoriasis research potential.

CCR8 antagonist 1 is an antagonist of C-C Motif Chemokine Receptor 8 (CCR8) with a Ki value of 1.6 nM.

Plozalizumab (MLN-1202) is a humanized selective and potent anti-CCR2 antibody.Plozalizumab has antitumor activity.Plozalizumab is used in the study of

Orally active CCR4 antagonist with piperidinyl-azetidine; IC50: 22 nM (calcium flux), 50 nM (CTX); antitumor effects.

Bertilimumab (CAT 213; iCo-008), a human monoclonal antibody that targets eotaxin-1 (CCL11), shows promise in the research of allergic disorders [1].

2-Methoxyhydroquinone inhibits MAO-A and MAO-B and reduces TNF-α-induced CCL2 production, a precursor for synthesising the Hsp90 inhibitor Geldanamycin.

CCR6 antagonist2 (Compound 20c) acts as a CCR6 antagonist with a Ki of 1.1 nM. It inhibits CCL20-induced calcium influx with an IC50 of 4.9 nM and suppresses the chemotactic migration of CCR6+ T cells with an IC50 of 190 nM.

INCB 3284 dimesylate: oral CCR2 antagonist, blocks MCP-1/hCCR2 binding (IC50: 3.7 nM), potential in acute liver failure research.

GSK163929 (compound 122) is an orally active CCR5 antagonist with anti-HIV properties and demonstrates low inhibitory potency against hEGR. Administered at a dosage of 2000 mg/kg/day (i.v., 7 d), it shows no adverse effects in rats, and at 250 mg/kg/day (i.v., 7 d), it is similarly non-toxic in dogs.

BMS-753426 is a potent and orally bioavailable antagonist of CCR2 .

HGS004 is a humanized IgG4 monoclonal antibody inhibitor targeting CCR5. It exhibits potent antiviral activity against various CCR5-tropic HIV-1 strains, including those resistant to other treatments (such as Maraviroc-resistant strains). HGS004 is applicable for research in HIV-1 infection.

Aplaviroc, a potent CCR5 inhibitor, binds selectively, blocking HIV entry and specific monoclonal antibody attachment in vitro.

PF-232798 is a second generation oral CCR5 antagonist with potent broad-spectrum anti-HIV-1 activity.

Orally active CCR4 antagonist 3 hydrochloride with potent selectivity, IC50s: 22/50 nM; has antitumor properties.

VZMC013 is a potent chemical probe targeting the MOR-CCR5 heterodimer, effectively inhibiting HIV-1 entry exacerbated by opioid compounds. It exhibits nanomolar binding affinity to both MOR and CCR5, inhibits CCL5-activated calcium mobilization, and significantly enhances anti-HIV-1BaL activity compared to previously reported bivalent ligands. In TZM-bl cells co-expressing CCR5 and MOR, VZMC013 demonstrates greater inhibition of viral infection than in cells expressing only CCR5. Additionally, VZMC013 blocks HIV-1 entry into peripheral blood mononuclear cells (PBMC) in a concentration-dependent manner and more effectively inhibits opioid-accelerated HIV-1 entry in phytohemagglutinin-activated PBMC than in opioid-free environments.

CMKLR1 antagonist 1 (compound S-26d) is a potent, orally active antagonist of the chemokine-like receptor 1 (CMKLR1), exhibiting a pIC50 of 7.44 in hCMKLR1-